Latest News

Discovery of how the gut loses protective barrier in IBD

Posted 07/03/2019
IBD pub
A single-cell based study from Prof Alison Simmons Lab describes clonic epithelial cell diversity in health and inflammatory bowel disease (IBD). Breakdown of the epithelial barrier underpins inflammatory bowel disease (IBD), and the authors show that WFDC2 preserves the integrity of tight junctions between epithelial cells and prevents invasion by commensal bacteria and mucosal inflammation. Simon Davis, Roman Fischer and Benedikt Kessler from the TDI participated in this study.
Big Data Institute announces two new research alliances

Big Data Institute announces two new research alliances

Posted 30/01/2019

The Big Data Institute (BDI) have recently announced new research alliances with Novartis and Sensyne Health; a five year collaboration with Novatis to establish a world-leading research alliance that will improve drug development by making it more efficient and more targeted.  And a 3 year alliance with Sensyne Health to advance the analysis and interpretation of NHS datasets

 

Oxford secures £17.5 million to lead national programmes in AI to improve healthcare

Oxford secures £17.5 million to lead national programmes in AI to improve healthcare

Posted 09/11/2018

Funding will be provided to the University of Oxford through the Government’s Industrial Strategy Challenge Fund by as part of a £50 million investment to establish a network of digital pathology, imaging and AI centres, to drive innovation in the use of AI for improved diagnosis and delivery of precision treatments.  Oxford is to be home to one of the five new technology centres across the country, and is also a collaborator in two of the other centres, with local activities integrated within the Big Data Institute

.

Novel cancer treatment resistance mechanism uncovered

Novel cancer treatment resistance mechanism uncovered

Posted 02/08/2018

BRCA1 deficiencies cause breast and ovarian cancer, rendering tumours hypersensitive to PARP inhibitors. Patient treatment can become ineffective due to emerging resistance mechanisms. Ross Chapman’s team at the Welcome Centre has uncovered a protein complex termed Shieldin that acts with 53BP1 to limit end resection at DNA double-strand breaks, which confers resistance to cancer treatment.

Sarah Bonham, Roman Fischer and Benedikt Kessler from the TDI were part of this study published in Nature.
 
Biomarker discovery for patients with malignant pleural effusion

Biomarker discovery for patients with malignant pleural effusion

Posted 15/06/2018

Ioannis Psallidas (Respiratory Medicine) and colleagues including members of the Target Discovery Institute  (TDI) (Benedikt Kessler Roman Fischer) have developed a score that predicts risk of death for a common metastasis of patients with malignant pleural effusion. Four proteins with a significant role in survival have been discovered, leading the road for new disease treatment. The PROMISE study results have been published in Lancet Oncology.

FORMA Therapeutics and the University of Oxford Announce Multi-Year Cross-Border Collaboration

FORMA Therapeutics and the University of Oxford Announce Multi-Year Cross-Border Collaboration

Posted 16/05/2018

The FORMA/Oxford collaboration brings together Oxford’s expertise in disease molecular pathology and Ubiquitin biology, (including through the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI), the Target Discovery Institute (TDI) and the Oxford Parkinson’s Disease Centre (OPDC)), and FORMA’s deep expertise in small molecule drug design and development.

 

Scientists discover promising ‘off-switch’ for inflammatory diseases

Scientists discover promising ‘off-switch’ for inflammatory diseases

Posted 03/04/2018

Researchers in Ireland, the UK and US have discovered a new metabolic process in the body that can switch off inflammation. “itaconate” – a molecule derived from glucose – “acts as a powerful off switch for macrophages”, thereby reducing inflammation. The discovery published in Nature offers more effective treatment of inflammatory diseases such as arthritis, inflammatory bowel disease and heart disease. Roman Fischer and Benedikt Kessler from the Target Discovery Institute (TDI) participated in this study.

 

The Journey from Genes to Disease – a symposium for postdocs by postdocs

The Journey from Genes to Disease – a symposium for postdocs by postdocs

Posted 26/03/2018

A free one day symposium, to be held on 20 April 2018, Medical Sciences Training Centre, Oxford and organised by the Postdoctoral Training Fellows at MRC Harwell Institute. The theme is the influence of genetics and genetic regulation in modelling human disease – from molecular through cellular to whole animal level and encompassing developmental, environmental and behavioural interactions.  Register here to attend for free.

 

Oxford one of six sites to receive funding for health data science

Oxford one of six sites to receive funding for health data science

Posted 27/02/2018

Health Data Research UK is awarding £30 million funding to six sites across the UK, including the University of Oxford, to address challenging healthcare issues through use of data science. Professor Martin Landray, Director of the Health Data Research UK Oxford site said: 'We are delighted that the Big Data Institute at University of Oxford will play a major part in Health Data Research UK. This exciting endeavour brings new opportunities to understand the causes of disease and to develop new treatments with substantial benefits for patients and public health.' 

 

New Year's Honours 2018

New Year's Honours 2018

Posted 04/01/2018

Congratulations to Professor Chas Bountra, Professor of Translational Medicine at the Nuffield Department of Medicine, who has been appointed OBE for services to Translational Medical Research in the New Year's Honours List 2018.  Congratulations also to 

Dr Jake Dunning, Honorary Visiting Research Fellow in Tropical Medicine (ERGO) who has been appointed MBE for services to Clinical Research.